Spartan 1 Bedside Genetic Tester

While whole-genome sequencing is moving in the right directions (better results, lower costs), it still will be a while before this is done as a point-of-care procedure with quick results.  Meanwhile, though, a Canadian company, Spartan Biosciences (Ottawa, Ont.) has developed and tested a bedside sequencer for a single gene variant that influences the efficacy of an anti-clotting drug as might be prescribed for patients who have had a stent inserted in a coronary artery. The company is issuing the device for free and charging $200 per test.  MORE

Image Credit: Spartan Biosciences and Technology Review